Treating newborns with antiretroviral therapy in the hours after birth may help put HIV into remission.
Jan. 16, 2020: Texting (and stigma support) vs. email for care retention; beyond-childhood health risks for HIV-exposed infants; HIV, cardiovascular risk, and cognitive impairment; direct-acting antiviral efficacy and prescription delays.
The impact of stigma on cognitive performance; risk factor dissonance among young black MSM; pregnancy and the HIV care continuum; new data on pediatric raltegravir use.
Kistin Nolan, M.P.H., and colleagues helped pilot a retention program designed to accommodate the emotional turmoil that makes it more difficult for young people with HIV to successfully navigate the health care system.
Despite their increased risk, only one-third of adolescents and young adults with known opioid use disorder were screened for hepatitis C, according to a study released at the IDWeek conference in San Francisco.
Results from a survey of people living with HIV in the UK who are aged 15-24 included the optimistic results that younger people might be experiencing less stigma than older HIV-positive people.
HIV incidence fell about 9% overall in a five-year span, the CDC found, but it rose in some groups, including people 25 to 29 years old, Asians, and American Indians.
A revolutionary method of HIV testing of infants, dried blood spot (DBS) testing, significantly cuts the time for diagnosis.
Rates of antiretroviral therapy prescription and sustained viral suppression rose in young U.S. adults from 2009 through 2013, according to a new study.
What's New in the U.S. HHS Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection
Text and references throughout the Guidelines were updated to include relevant new data and publications.